>>Description of the research protocol "AEGISII"

Phase 3, Multicenter, Double-Blind, Randomized, Placebo-controlled, Parallel-group study to investigate the efficacy and safety of CSL112 in Subjects with acute coronary syndrome
Phase III study| Status : Ongoing and recruiting

Additional details

Indication (or studied pathology) : Cardiologie
Brugmann identifier : AEGISII
EudraCT identifier : 2017-000996-98
ClinicalTrials.gov identifier : NCT03473223


Involved department : Cardiology
Principal investigator : Castro
Sponsor : CSL Behring
Contact : Clinical Research Unit

>This protocol was approved by the KU Leuven ethics committee.